tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Entrada Therapeutics Inc

TRDA
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
5.090USD
-0.080-1.55%
์ข…๊ฐ€ย 11-13 16:00๏ผˆET๏ผ‰
198.20M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM

Entrada Therapeutics Inc ์ •๋ณด ํšŒ์‚ฌ

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. It is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Entrada Therapeutics Inc ํ”„๋กœํ•„

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ TRDA
ํšŒ์‚ฌ ์ด๋ฆ„Entrada Therapeutics Inc
์ƒ์žฅ์ผOct 29, 2021
CEODoshi (Dipal)
์ง์› ์ˆ˜183
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒOct 29
์ฃผ์†ŒOne Design Center Place
๋„์‹œBOSTON
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ02210
์ „ํ™”18573051825
์›น์‚ฌ์ดํŠธhttps://www.entradatx.com/
์ข…๋ชฉ ์ฝ”๋“œ TRDA
์ƒ์žฅ์ผOct 29, 2021
CEODoshi (Dipal)

Entrada Therapeutics Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Peter S. Kim, Ph.D.
Dr. Peter S. Kim, Ph.D.
Director
Director
129.33K
+19.33%
Dr. Natarajan Sethuraman, Ph.D.
Dr. Natarajan Sethuraman, Ph.D.
President of Research and Development
President of Research and Development
78.69K
-2.64%
Mr. Nathan J. Dowden
Mr. Nathan J. Dowden
President, Chief Operating Officer
President, Chief Operating Officer
36.05K
-7.01%
Mr. Kory James Wentworth, CPA
Mr. Kory James Wentworth, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
13.40K
-12.93%
Mr. Dipal Doshi
Mr. Dipal Doshi
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
Dr. Kush M. Parmar, M.D., Ph.D.
Dr. Kush M. Parmar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Ms. Gina Chapman
Ms. Gina Chapman
Independent Director
Independent Director
--
--
Dr. Mahalakshmi (Maha) Radhakrishnan, M.D.
Dr. Mahalakshmi (Maha) Radhakrishnan, M.D.
Independent Director
Independent Director
--
--
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Peter S. Kim, Ph.D.
Dr. Peter S. Kim, Ph.D.
Director
Director
129.33K
+19.33%
Dr. Natarajan Sethuraman, Ph.D.
Dr. Natarajan Sethuraman, Ph.D.
President of Research and Development
President of Research and Development
78.69K
-2.64%
Mr. Nathan J. Dowden
Mr. Nathan J. Dowden
President, Chief Operating Officer
President, Chief Operating Officer
36.05K
-7.01%
Mr. Kory James Wentworth, CPA
Mr. Kory James Wentworth, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
13.40K
-12.93%
Mr. Dipal Doshi
Mr. Dipal Doshi
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Entrada Therapeutics Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Entrada Therapeutics Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค: Dr. Peter S. Kim, Ph.D.

Entrada Therapeutics Inc(TRDA)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2026Q1 ๊ธฐ์ค€์œผ๋กœ, Entrada Therapeutics Inc์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 267๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 31.31M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 80.65%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q4 ๋Œ€๋น„ -1502811.00 ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ